Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte beats estimates on high demand for cancer drug Jakafi
08:24am, Tuesday, 01'st Aug 2023
Incyte Corp on Tuesday reported second-quarter profit and revenue above Wall Street estimates as demand for its blood cancer drug Jakafi and skin disorder drug Opzelura picked momentum.
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
12:34pm, Wednesday, 12'th Jul 2023
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
Incyte skin disease drug for children meets main goal in late-stage study
04:23pm, Tuesday, 11'th Jul 2023
Incyte Corp said on Tuesday its experimental drug to treat a skin condition in children between the age of two to twelve met the primary goal in a late-stage study.
New Strong Sell Stocks for June 16th
08:35am, Friday, 16'th Jun 2023
ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
04:51pm, Tuesday, 02'nd May 2023
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates
09:54am, Tuesday, 02'nd May 2023
Incyte (INCY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.55 per share a year ago.
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
12:11pm, Wednesday, 26'th Apr 2023
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
02:26pm, Friday, 21'st Apr 2023
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
7 Biotech Stocks That Could Cure Your Portfolio Woes
07:22pm, Wednesday, 19'th Apr 2023
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday
04:28pm, Monday, 10'th Apr 2023
Micron Technology and Charles Schwab were among the top S&P 500 stock performers on Monday. Expedia was a notable loser.
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
01:42pm, Thursday, 06'th Apr 2023
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
Incyte (INCY) Down 9.6% so Far in 2023 on Recent Setbacks
06:15pm, Wednesday, 05'th Apr 2023
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
01:45pm, Monday, 27'th Mar 2023
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
FDA Rejection Pushes Incyte Stock Sharply Lower
11:05am, Friday, 24'th Mar 2023
The shares of Incyte Corporation ( NASDAQ:INCY) are down 5.3% at $68.33 at last check, after the U.S. Food and Drug Administration (FDA) failed to approve the extended-release version of the compan
Incyte Stock Dives On Surprise Rejection For Updated Jakafi
09:17am, Friday, 24'th Mar 2023
Incyte stock toppled Friday after the FDA unexpectedly rejected an extended-release version of its blockbuster drug, Jakafi. The post Incyte Stock Dives On Surprise Rejection For Updated Jakafi appear
